Correction to: Scientific Reports https://doi.org/10.1038/s41598-022-25418-5, published online 02 December 2022
The original version of this Article contained an error in Figure 6 where panel (e) was omitted. The original Figure 6 and accompanying legend appear below.
Induction of long-term immunity in mice administered S-910823 plus A-910823. (a) Study schedule schematic. On Day 0 and Day 14, female mice were intramuscularly administered 1 μg of S-910823 with or without A-910823 (n = 5/group). Spleens and bone marrow were collected on Day 83. (b) Flow cytometric analysis of the percentage of receptor-binding domain (RBD)-specific B-cells among CD73+CD19+ B-cells. Each circle represents the percentage of cells in an individual mouse. The bars represent mean values, while error bars indicate standard deviation. (c) Detection of vaccine-induced antibody-secreting cells (ASCs) in bone marrow. Bone marrow cells were cultured for 2.5 h in an enzyme-linked immunospot (ELISPOT) assay plate wells which had been coated with SARS-CoV-2 spike protein. Results indicate the number of antigen-specific ASCs among 106 bone marrow cells. (d, e) Percentage of cytokine-producing T cells in the spleen. Splenocytes were restimulated ex vivo with or without SARS-CoV-2 spike-protein-derived peptides for 16 h. Levels of IL-2, IFN-γ, TNF-α, IL-4, and IL-5 from CD44+CD4+ T cells (d) and levels of IFN-γ from CD44+CD8+ T cells (e) were evaluated using cell-surface and intracellular staining and examined using flow cytometry. The open bars indicate non-stimulated splenocytes [peptide (−)], while the solid bars indicate splenocytes stimulated with SARS-CoV-2 spike protein peptides [peptide (+)]. The gray bars represent mice administered vehicle or S-910823 without adjuvant A-910823, while the rose bars represent mice administered S-910823 with A-910823. The open and solid circles represent the results of individual mice. The error bars indicate the standard deviation.
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Homma, T., Nagata, N., Hashimoto, M. et al. Author Correction: Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice. Sci Rep 14, 2599 (2024). https://doi.org/10.1038/s41598-024-52772-3
Published:
DOI: https://doi.org/10.1038/s41598-024-52772-3
